[Comparative evaluation of mexiletine and propafenone by dynamic electrocardiography].
We have compared the efficacy of Propafenon and Mexiletine in 12 subjects (7 males and 5 females, age range of 22-61 year) affected by chronic ventricular extrasystolic beats. Propafenon and Mexiletine were orally administered in doses of 900 mg/day and 600 mg/day respectively in a single blind, cross-over fashion. Our results show that: Propafenon is better tolerated; Propafenon has caused a statistically significant reduction of the total number of ventricular ectopic beats/24 hours; the efficacy of Propafenon has been greater than that of Mexiletine (66% and 25% respectively); with both drugs, in 2 cases, there was an increase of the total number of ventricular ectopic beats/24 hours; Propafenon has induced clear-cut electrocardiogram changes (statistically significant lengthening of P-Q and Q-T intervals).
D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D004341:Drug Evaluation; D004562:Electrocardiography / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D008801:Mexiletine / Q000627:therapeutic use*; D008875:Middle Aged; D011405:Propafenone; D011427:Propiophenones / Q000627:therapeutic use*; D011437:Propylamines / Q000627:therapeutic use*
D000889:Anti-Arrhythmia Agents; D011427:Propiophenones; D011437:Propylamines; D008801:Mexiletine; D011405:Propafenone
Valutazione comparativa tra mexiletina e propafenone mediante elettrocardiogramma dinamico.